SCHEMBL9902814

SCHEMBL9902814

Nc1cnc(C(F)(F)F)nc1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.34
CHKA P35790 1/20 0.34
PTGS1 P23219 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
KIF11 P52732 1/20 0.32
DHFR P00374 1/20 0.31
TSHR P16473 3/20 0.31
GLA P06280 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
MAPK1 P28482 1/20 0.31
TRPV4 Q9HBA0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1169515 0.74 HTT (0.35) ALDH1A1TRPV4
SCHEMBL10600401 0.74 TRPV4 (0.32) TRPV4
SCHEMBL10775633 0.72 TRPV4 (0.31) CA2CHKATRPV4
SCHEMBL17619921 0.72 TRPV4 (0.31) TRPV4
SCHEMBL14865436 0.72 TRPV4 (0.31) TRPV4
SCHEMBL156478 0.72 HTT (0.39) ALDH1A1GLATRPV4
SCHEMBL254676 0.72 APLNR (0.39) ALDH1A1NOS3NOS2TRPV4
SCHEMBL876534 0.72 DEGS1 (0.34) KIF11TRPV4
SCHEMBL599774 0.72 KDM4E (0.37) POLB
SCHEMBL20003501 0.72 TRPV4 (0.52) TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125375-A1 SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS PFIZER INC. (US) 2026-05-07 US disclosed
US-12610730-B2 Metal complex and light emitting device CITY UNIVERSITY OF HONG KONG (HK) 2026-04-21 US disclosed
US-20260014119-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-15 US disclosed
EP-4676480-A1 INHIBITORS OF DNA POLYMERASE THETA Breakpoint Therapeutics GmbH (DE) 2026-01-14 EP disclosed
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2026-01-08 US disclosed
EP-4667054-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2025-12-24 EP disclosed
US-12448369-B2 Quinolinone amide compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-10-21 US disclosed
EP-3880660-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2025-07-02 EP disclosed
US-20250206722-A1 SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS THE SCRIPPS RESEARCH INSTITUTE 2025-06-26 US disclosed
EP-4554934-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 EP disclosed
EP-2718271-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-04-16 EP disclosed
US-20140073620-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-03-13 US disclosed
WO-2014026243-A1 VEGFR3 INHIBITORS CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2014-02-20 WO disclosed
CN-103596937-A Substituted benzamide derivatives HOFFMANN LA ROCHE 2014-02-19 CN disclosed
US-20130310374-A1 Substituted Imidazoquinoline Derivatives PIRAMAL ENTERPRISES LIMITED` (IN) 2013-11-21 US disclosed
CN-103402520-A Substituted imidazoquinoline derivatives PIRAMAL LIFE SCIENCES LTD 2013-11-20 CN disclosed
EP-2648733-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES Piramal Enterprises Limited (IN) 2013-10-16 EP disclosed
WO-2012168265-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-12-13 WO disclosed
US-20120316165-A1 SUBSTITUTED BENZAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. 2012-12-13 US disclosed
WO-2012077031-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014119-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBP, EBPL, ELP1 CA2 3616/4885CHKA 2304/4885PTGS1 601/4885
US-20250206722-A1 SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS YAP1, TEAD1, TEAD2 CA2 3241/4885CHKA 2667/4885PTGS1 1569/4885
US-12448369-B2 Quinolinone amide compounds and uses thereof TNNI3, TNNT2, COQ8A CA2 622/4885CHKA 1408/4885PTGS1 867/4885
US-12610730-B2 Metal complex and light emitting device OPRD1, OCIAD2, ORC3 CA2 2417/4885CHKA 3914/4885PTGS1 3095/4885
US-20130310374-A1 Substituted Imidazoquinoline Derivatives FLT4, CDK4, CDK2 CA2 3095/4885CHKA 957/4885PTGS1 52/4885
US-20260125375-A1 SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS CCR1, CCR6, CCRL2 CA2 1848/4885CHKA 1230/4885PTGS1 2502/4885
US-20120316165-A1 SUBSTITUTED BENZAMIDE DERIVATIVES NPY4R, PER2, NPY1R CA2 2365/4885CHKA 2083/4885PTGS1 3912/4885
US-20140073620-A1 VEGFR3 INHIBITORS FLT4, FLT1, KDR CA2 3803/4885CHKA 3097/4885PTGS1 486/4885
US-20260008774-A1 QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF TNNT2, TNNI3, TNNC1 CA2 193/4885CHKA 1773/4885PTGS1 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.